Radar · Oncology in South Korea
Best Oncology Companies in South Korea
The 232 best Oncology companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
By Rohit KhannaTrends & Stories
232companies tracked
$3.8Bdisclosed funding
1unicorns
68have raised
South Korea's oncology sector is one of the more quietly serious bets in Asian biotech right now, and this page ranks the best oncology companies in South Korea by disclosed equity funding and recent funding momentum across 232 tracked firms. Total disclosed capital sits at $3.8B. One unicorn has emerged. And the funding is concentrating fast around a handful of names worth knowing.
Orum Therapeutics leads at $92M raised, with Must Bio ($24M), 1ST Bio ($22M), MediMabBio ($18M), and Novorex ($15M) filling out the upper tier. The global oncology market is forecast to grow at 11.5% CAGR through 2034, so the macro tailwind isn't subtle. Precision medicine and cancer biomarkers are the dominant R&D themes here, which tracks with what you're seeing across Asia broadly, including India's accelerating pivot to targeted therapies. Cost-containment policies add friction, I'll grant that, but Korea Investment Holdings and IMM Investment are still writing checks. The pipeline is moving.
Sources & further reading
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
FLIAR INTELLIGENCE · ONCOLOGY × SOUTH KOREA
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
Ranked: Best Oncology companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | Public | 68 | — | Top 5M | 32 patents Patents concentrated in chemistry & materials | — |
| 2 | Genexine Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders 40Product top 14%Patents top 25%Innovation top 32%Funding top 38% All 11 signals ▾Producttop 14% Patentstop 25% Innovationtop 32% Fundingtop 38% Talenttop 38% Moattop 41% Growthtop 45% Globalbottom 45% Marketbottom 37% Fin. healthbottom 34% Techbottom 23% Product: 10 distinct product lines · Company stage: Public Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $233M | 98 mo ago | Public | — | Young Sung Founder & Chairman | Top 10M | 357 patents Therapeutic protein engineering and antibody-based cancer immunotherapies. | — |
| 3 | Orum Therapeutics Developer of cell-penetrating antibodies as oncology therapeutics 55Funding top 19%Patents top 23%Moat top 26%Innovation top 35% All 10 signals ▾Fundingtop 19% Patentstop 23% Moattop 26% Innovationtop 35% Talenttop 41% Growthtop 47% Globalbottom 47% Marketbottom 44% Techbottom 42% Newsbottom 41% Funding: Raised $92.0M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Patents: 121 patents matched (strict assignee match) · 66 filings since 2022 vs 53 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $92M | 6 mo ago | Public | 38 | Sj Lee CEO | Top 5M | 121 patents Targeted antibody‑drug conjugates and neodegrader therapeutics for CD123 and T‑cell activation | — |
| 4 | Curocell Developer of immune cell therapies 57Talent top 28%Funding top 34%Patents top 34%Moat top 38% All 8 signals ▾Talenttop 28% Fundingtop 34% Patentstop 34% Moattop 38% Innovationtop 42% Markettop 46% Techbottom 42% Globalbottom 40% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $82.4M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $82M | 53 mo ago | Series D | 102 | Chan Kim Co-Founder & CTO | Top 5M | 40 patents CD5-targeted engineered immune cells and antibodies for cancer immunotherapy | — |
| 5 | ABL Bio Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 96 mo ago | Public | 93 | Sang Hoon Lee Ceo/Founder | Top 5M | 273 patents Bispecific therapeutic antibodies targeting tumor antigens and immune co‑stimulatory receptors | — |
| 6 | ImmuneOncia Developer of monoclonal and specific antibody for cancer treatment 11Funding top 37%Moat top 39%Market bottom 32%Global bottom 32% All 5 signals ▾Fundingtop 37% Moattop 39% Marketbottom 32% Globalbottom 32% Techbottom 23% Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 53 mo ago | Public | 21 | — | Top 50M | — | — |
| 7 | Rznomics Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology 57Growth top 15%Patents top 28%Moat top 32%Innovation top 33% All 9 signals ▾Growthtop 15% Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 38% Talentbottom 49% Marketbottom 44% Globalbottom 42% Techbottom 22% Growth: Web rank 50,000,000 → 5,000,000 YoY Patents: 61 patents matched (strict assignee match) · 51 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $49M | 48 mo ago | Public | 39 | Seong-Wook Lee Founder & CEO | Top 5M | 61 patents Therapeutic circular RNA and trans‑splicing ribozyme platforms for gene‑editing and drug delivery | — |
| 8 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 83 mo ago | Series B | 58 | Dong Hoon Co-Founder & Co-CEO | — | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 9 | ILIAS Biologics Developer of exosome based therapeutics | $40M | 68 mo ago | Series B | 21 | — | — | 62 patents Targeted exosome delivery of NF-κB inhibitory antibodies for liver disease therapy | — |
| 10 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 54 mo ago | Series C | 24 | — | — | — | — |
| 11 | Onconic Therapeutics Developer of therapeutics for the treatment of cancer and gastrointestinal diseases 24Patents top 22%Innovation top 25%Moat top 29%Funding top 36% All 10 signals ▾Patentstop 22% Innovationtop 25% Moattop 29% Fundingtop 36% Talentbottom 49% Globalbottom 42% Newsbottom 37% Growthbottom 30% Marketbottom 23% Techbottom 17% Patents: 114 patents matched (strict assignee match) · 107 filings since 2022 vs 7 in 2017-21 Innovation: 114 patents (top 24% of patent-holders) · 107 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 24/100 | $35M | 42 mo ago | Public | 6 | John Kim CEO | Top 10M | 114 patents Solid-form and salt optimization of heterocyclic anticancer small‑molecule therapeutics | — |
| 12 | IMBiologics Developer of antibody therapeutics to treat cancer and autoimmune diseases 40Moat top 32%Funding top 33%Patents top 36%Innovation top 45% All 6 signals ▾Moattop 32% Fundingtop 33% Patentstop 36% Innovationtop 45% Marketbottom 41% Globalbottom 40% Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $34M | 34 mo ago | Public | 25 | — | — | 23 patents Engineered therapeutic antibodies/fusion proteins with extended half-life and bispecific immune targeting | — |
| 13 | Aprogen 🦄 Biotechnology company producing Biosimilars | $31M | 85 mo ago | Late Stage | 66 | — | Top 10M | 63 patents Therapeutic antibody formulations targeting TNF‑α and CD43 for inflammatory and cancer treatments | — |
| 14 | Kanaph Developer of immunocytokine platform for treating cancer | $30M | 68 mo ago | Public | 13 | Byoung Lee CEO | Top 10M | 2 patents Chain retention mechanisms for foldable bicycles preventing chain separation. | — |
| 15 | Zymedi Developer of therapeutics for multiple diseases 29Patents top 31%Moat top 32%Innovation top 40%Funding top 41% All 9 signals ▾Patentstop 31% Moattop 32% Innovationtop 40% Fundingtop 41% Growthtop 45% Talentbottom 49% Globalbottom 35% Marketbottom 25% Techbottom 23% Patents: 31 patents matched (strict assignee match) · 28 filings since 2022 vs 3 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 31 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $30M | 36 mo ago | Series A | — | Nam Kwon CEO | Top 50M | 31 patents Immunomodulatory drugs targeting Lysyl‑tRNA synthetase to control immune cell migration | — |
| 16 | Tikaros Developer of immunotherapies for the treatment of cancer | $24M | 57 mo ago | Series C | — | Kyungho Choi Co-Founder | Top 50M | — | — |
| 17 | Must Bio Developer of immunotherapeutics for cancer treatment 27Funding top 29%Talent bottom 49%Market bottom 36%Global bottom 29% All 4 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $24M | 3 mo ago | Series C | 18 | Kim Seop CEO | — | — | — |
| 18 | Progen Developer of immunotherapies for immune diseases and cancer 62Growth top 5%Partners top 18%News top 19%Moat top 25% All 10 signals ▾Growthtop 5% Partnerstop 18% Newstop 19% Moattop 25% Patentstop 39% Innovationtop 48% Fundingbottom 49% Talentbottom 49% Marketbottom 48% Globalbottom 36% Partners: 5 contract events in 12 mo · Named contractor/client in 5 deals rank vs industry peers · Fliar Intelligence Index 62/100 | $23M | 38 mo ago | Series B | — | Jong Kim CEO | — | 73 patents Engineered Fc-fusion and bispecific therapeutic proteins, including IL-10 variants, for biologics. | — |
| 19 | 1ST Bio Developer of therapies for treating neurodegenerative and immuno-oncology diseases 53Funding top 28%Talent top 28%Market bottom 46%Global bottom 37% All 4 signals ▾Fundingtop 28% Talenttop 28% Marketbottom 46% Globalbottom 37% Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | Series D | 34 | — | — | — | — |
| 20 | Pharmcadd Provider of CAAD based drug discovery platform | $22M | 62 mo ago | Series B | 35 | Woo Wook Founder | — | 21 patents AI-based protein structure prediction and piperidine-derived drug discovery | — |
| 21 | Avelos Therapeutics Developer of biomarker-driven anti-cancer targeted therapies 32Moat top 32%Patents top 37%Innovation top 41%Funding top 43% All 7 signals ▾Moattop 32% Patentstop 37% Innovationtop 41% Fundingtop 43% Talentbottom 49% Globalbottom 36% Marketbottom 32% Moat: Editorial + unicorn rating 4/10 · IP moat: 29 patents Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $20M | 25 mo ago | Series B | 15 | Young-Whan Park Founder & CEO | — | 29 patents Novel heterocyclic small‑molecule scaffolds for therapeutic drug discovery | — |
| 22 | Haim Bio Developer of anticancer drug that block metabolic pathways | $20M | 55 mo ago | Series B | — | Hong Kim CEO | — | — | — |
| 23 | TRIOAR Developer of drugs for the treatment of cancer 29Moat top 38%Funding top 39%Patents top 41%Innovation top 47% All 7 signals ▾Moattop 38% Fundingtop 39% Patentstop 41% Innovationtop 47% Talentbottom 49% Marketbottom 34% Globalbottom 31% Moat: Editorial + unicorn rating 4/10 · IP moat: 18 patents Funding: Raised $18.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 11 mo ago | Series B | 16 | Seongho Woo CEO | — | 18 patents Targeted cancer antibody-drug conjugates using novel cleavable linkers for claudin‑18.2 | — |
| 24 | Eutilex Developing T cell-based therapeutics and antibodies for the treatment of cancer. | $18M | 114 mo ago | Public | 103 | Byoung Kwon Founder & CEO | Top 10M | 191 patents Immuno‑oncology therapeutics: checkpoint antibodies, bispecifics, CAR‑T, and immune adjuvants | — |
| 25 | MediMabBio Developer of immunotherapeutics for treating cancer 29Moat top 32%Funding top 35%Talent top 38%Patents top 40% All 8 signals ▾Moattop 32% Fundingtop 35% Talenttop 38% Patentstop 40% Innovationtop 42% Globalbottom 31% Marketbottom 30% Techbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 7 mo ago | Series B | 19 | Hongseok Jo Co-Founder | Top 50M | 28 patents Immune checkpoint antibodies (TIGIT, GITR) and cytokine‑fusion therapeutics for cancer immunotherapy | — |
| 26 | Uvic Steratics Developer of anti-cancer drugs based on Proteolysis Targeting Chimera 27Funding top 39%Talent bottom 49%Market bottom 39%Tech bottom 37% All 5 signals ▾Fundingtop 39% Talentbottom 49% Marketbottom 39% Techbottom 37% Globalbottom 37% Funding: Raised $17.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $18M | 17 mo ago | Series B | 41 | Servo Optical CEO | Top 50M | — | — |
| 27 | Daan Biotherapeutics Developer of therapeutics for cancer treatment 19Moat top 38%Talent top 38%Patents top 43%Funding top 44% All 9 signals ▾Moattop 38% Talenttop 38% Patentstop 43% Fundingtop 44% Innovationbottom 47% Globalbottom 40% Growthbottom 35% Techbottom 31% Marketbottom 19% Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 19/100 | $17M | 28 mo ago | Series A | 4 | J Han Founder | Top 10M | 8 patents Targeted cancer immunotherapy: anti-CEACAM5 antibodies and engineered T‑cell receptor therapies. | — |
| 28 | Centenaire Biosciences Developer of antibody therapies to treat cancer and immune diseases | $16M | 50 mo ago | Series A | — | Yang Cheol CEO | Top 5M | 14 patents Engineered multi‑Fc antibody fusion proteins for enhanced therapeutic binding and effector functions. | 2 launchs · 1 partnership |
| 29 | MedPacto Company developing ALK-5 kinase inhibitors for treating solid tumors and multiple myeloma | $16M | 65 mo ago | Public | 62 | — | Top 50M | 107 patents Targeted antibody therapeutics and diagnostics for oncology and metabolic liver disease | — |
| 30 | Pharos iBio Provider of therapeutics for oncology and rare disease | $16M | 59 mo ago | Public | 22 | Jeonghyeok Yoon CEO | — | 36 patents Small-molecule kinase inhibitors targeting KIT/PDGFRA for oncology therapeutics | — |
| 31 | CTCELLS Developer of cell-based therapeutics for oncology | $15M | 50 mo ago | Series B | — | Minseok Kim CEO | Top 50M | 43 patents Cell separation and rare cell isolation technologies, plus NK cell differentiation and fusion protein therapeutics. | — |
| 32 | NOVOREX Developer of drugs for the treatment of cancer and central nervous diseases 32Funding top 33%AI top 45%Moat top 45%Patents top 50% All 8 signals ▾Fundingtop 33% AItop 45% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Globalbottom 36% Marketbottom 34% Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 1 mo ago | Series B | 20 | Woosung Son CEO | — | 4 patents Small‑molecule inhibitors of LRRK2 kinase and YEATS epigenetic reader domains | — |
| 33 | MetaFines Developer of anticancer drugs using cancer metabolism | $15M | 49 mo ago | Series B | 15 | Bae Cheol-min CEO | — | 15 patents Metal-chelate anticancer drugs and cachexia/muscle‑loss therapeutic formulations. | — |
| 34 | Oncocross Provider of AI-based drug discovery platform | $14M | 69 mo ago | Public | 10 | Jin Choi Co-Founder | Top 10M | 132 patents AI-driven drug discovery and predictive therapeutics for cancer, kidney, and muscle diseases | 1 partnership |
| 35 | Bertis Developer of AI-based diagnostic platform for cancer and cardiac diseases | $13M | 60 mo ago | Series B | 46 | Inhoi Koo Co-Founder | Top 50M | 81 patents Cancer biomarker detection using advanced mass spectrometry and liquid chromatography methods | — |
| 36 | Neogen TC Developer of cell therapies for the treatment of cancer | $13M | 62 mo ago | Series A | — | Heejin Lee CEO | — | — | — |
| 37 | Boostimmune Developer of therapeutics for cancer treatment | $13M | 47 mo ago | Series A | 5 | Tadatsugu Taniguchi Co-Founder | — | 10 patents TCTP-based cancer biomarkers and therapeutic agents for immune‑modulating oncology. | — |
| 38 | NGeneBio In vitro cancer diagnostic products | $13M | 90 mo ago | Public | 124 | Min-Sik Kim Co-CEO | Top 10M | 46 patents Genetic diagnostics and personalized therapeutics via nucleic‑acid amplification and microbiome analysis | — |
| 39 | SillaJen Developer of oncolytic immunotherapeutics for the treatment of cancer | $12M | 122 mo ago | Public | 49 | — | Top 10M | 113 patents Oncolytic virus therapies and advanced drug delivery formulations for cancer treatment | — |
| 40 | Olive Healthcare Provider of device for wellness and medical purpose | $10M | 77 mo ago | Series B | 24 | Sung Han Founder & CEO | — | 60 patents Breast cancer diagnostic imaging devices (ultrasound/NIR) and body composition analysis tools. | — |
| 41 | SCBIO Developer of small molecule immuno-oncology drugs 27Funding top 42%Moat top 45%Patents top 50%Talent bottom 45% All 7 signals ▾Fundingtop 42% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Marketbottom 37% Globalbottom 31% Funding: Raised $10.1M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $10M | 9 mo ago | Series B | 23 | Chang Lee CEO | — | 4 patents Livestock feed additives reducing methane emissions and HDAC6 enzyme inhibitors for therapeutics | — |
| 42 | Bridge Biotherapeutics Developer of small molecule based therapeutics for the treatment of various diseases | $10M | 107 mo ago | Acquired | 6 | James Jungkue Lee Founder & CEO | Top 5M | 36 patents Small‑molecule autotaxin inhibitors and PROTACs for targeted protein degradation therapies. | — |
| 43 | Portrai Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification 22Patents top 37%Funding top 38%Innovation top 41%Global bottom 35% All 5 signals ▾Patentstop 37% Fundingtop 38% Innovationtop 41% Globalbottom 35% Marketbottom 22% Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 6 mo ago | Series B | 7 | — | — | 29 patents Patents concentrated in computing, sensing & instrumentation | — |
| 44 | Txinno Developer of therapeutics for the treatment of cancer | $8M | 57 mo ago | Series A | 25 | Chan-Sun Park CEO & Co-Founder | — | — | — |
| 45 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 76 mo ago | Series A | 33 | Sang Park Founder & CEO | — | 55 patents Therapeutic antibodies and ADCs targeting c‑Kit, CDCP1, VEGF, HIF‑1α for cancer and mast‑cell diseases | — |
| 46 | Ingenium Therapeutics Developer of anti-cancer immunotherapy treatments | $4M | 30 mo ago | Series A | 14 | Sangyong Kim Co-Founder | — | 5 patents NK cell activation agents for immunotherapy | — |
| 47 | VS PharmTech Developer of anticancer drugs and adjuvants 27Moat top 32%Patents top 39%Funding top 47%Innovation top 50% All 6 signals ▾Moattop 32% Patentstop 39% Fundingtop 47% Innovationtop 50% Globalbottom 40% Marketbottom 36% Moat: Editorial + unicorn rating 5/10 · IP moat: 98 patents Patents: 98 patents matched (strict assignee match) · 12 filings since 2022 vs 33 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $4M | 9 mo ago | Series B | 18 | — | — | 98 patents Ophthalmic drug formulations using recoflavone for dry eye treatment | — |
| 48 | EPD Biotherapeutics Developer of targeted protein-degrading therapeutics for cancer and neurological disorders | $3M | 47 mo ago | Seed | 2 | Seunghyun Lee Co-Founder | — | — | — |
| 49 | CrossPoint Therapeutics Developer of immunotherapies for cancer treatment 27Moat top 45%Patents top 47%Funding bottom 46%Talent bottom 45% All 6 signals ▾Moattop 45% Patentstop 47% Fundingbottom 46% Talentbottom 45% Innovationbottom 40% Globalbottom 31% Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents Patents: 5 patents matched (strict assignee match) · 5 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | Seed | — | Tae-Erk Kim Co-Founder & CEO | — | 5 patents Engineered Fc-domain antibodies for ADCs and bispecific therapeutic formats | — |
| 50 | OncoLaB Developer of antibody-conjugated nanogel platform for targeted cancer therapeutics delivery 35Funding bottom 49%Talent bottom 45%Global bottom 33% All 3 signals ▾Fundingbottom 49% Talentbottom 45% Globalbottom 33% Funding: Raised $687k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 35/100 | $687K | 7 mo ago | Seed | — | Jongseong Kim Founder & CEO | — | — | — |
Top 12 Oncology companies in South Korea
#1
Public · Daejeon, Daejeon · founded 2016 · 38 employees$92Mraised▾
Public · Daejeon, Daejeon · founded 2016 · 38 employees
Developer of cell-penetrating antibodies as oncology therapeutics. It has a proprietary cell-penetrating antibody technology and is developing monoclonal antibodies to directly target the activated form of RAS. The cell-penetrating technology develops antibodies that can access the cytosol of living cells following receptor-mediated endocytosis. RAS proteins function to transmit signals within cells that control cell growth, differentiation, and survival. The product pipeline includes ORM-5029, ORM-6151, and ANDC-0001 for solid tumors and hematological cancers
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 19%Patents
top 23%Moat
top 26%Innovation
top 35%Talent
top 41%Growth
top 47%Funding: Raised $92.0M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) · Last round Post IPO (Dec 2025)
Patents: 121 patents matched (strict assignee match) · 66 filings since 2022 vs 53 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 121 patents · Soonicorn
Audience (LinkedIn): 7k LinkedIn followers — 23.3% of this cohort's audience · 87 engagements/post (2.1× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public)
Funding rounds
- Dec 2025Post IPO$100M
- Jun 2021Series B$54M
- Jul 2019Series B$30M
- Jun 2017Series A$8M
Founders & team
Investors
IMM Investment, KDB Investment, Atinum Investment, InterVest, KB Investment, Smile Gate Investment
Tech stack
AngularCart FunctionalityCore-JsGodaddyGoogle Font ApiGoogle Workspace
#2
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 33%AI
top 45%Moat
top 45%Patents
top 50%Talent
bottom 45%Innovation
bottom 38%Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Apr 2026)
AI: Product described with: artificial intelligence
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Funding rounds
- Apr 2026Series B$15M
Founders & team
Investors
KB Investment, UTC Investment, Korean Development Bank, SBI Investment, Hyundai Venture Investment, K&Investment Partners
#3
Series C · Seoul, Seoul · founded 2021 · 18 employees$23.5Mraised▾
Series C · Seoul, Seoul · founded 2021 · 18 employees
Developer of immunotherapeutics for cancer treatment. It offers multi-specific antibodies which include MB101, MB201, MB301, and MB401 for the treatment of multiple cancer. It offers multi-antibody platform technology to develop multiple antibodies.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 29%Talent
bottom 49%Market
bottom 36%Global
bottom 29%Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Market: 18 employees
Funding rounds
- Mar 2026Series C$23.5M
- Series A—
- Series B—
Founders & team
Investors
Premier Partners, Partners Investment, Korean Development Bank, Wonik Investment Partners, Shinhan Financial Group, Atinum Investment
#4
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Market
bottom 46%Global
bottom 37%Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series D (Jan 2026)
Talent: Analyst team rating 4/5
Market: 34 employees (top 46% of Life Sciences)
Funding rounds
- Jan 2026Series D$22M
Investors
Smile Gate Investment, LigaChemBio, Korea Investment Holdings, Anda Asset Management, Daily Partners, Mirae Asset
#5
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 32%Funding
top 35%Talent
top 38%Patents
top 40%Innovation
top 42%Global
bottom 31%Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents
Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Oct 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 571 LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$17.8M
Founders & team
Investors
KB Investment, Smile Gate Investment, BNH INVESTMENT, Hyundai-invest.com, iM Investment Partners, Time Polio Asset Management
Tech stack
Apache Http ServerBootstrapCookieyesGoogle AnalyticsGoogle Font ApiJquery
#6
Series B · Seoul, Seoul · founded 2021 · 7 employees$9.9Mraised▾
Series B · Seoul, Seoul · founded 2021 · 7 employees
Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification. The platform allow researchers to analyse the pathophysiology of diseases and discovers biomarkers, identify targets for new drugs, analyse the mode of action of drugs, and discover biomarkers.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Patents
top 37%Funding
top 38%Innovation
top 41%Global
bottom 35%Market
bottom 22%Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Dec 2025)
Innovation: 29 patents (top 60% of patent-holders) · 29 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 639 LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Dec 2025Series B$9.9M
Investors
STIC Ventures, BNH INVESTMENT, Kakao Ventures, Envisioning Partners, BonAngels Venture Partners, Pearl Abyss Capital
#7
Seed · Hwaseong, Gyeonggi do · founded 2022$2.4Mraised▾
Seed · Hwaseong, Gyeonggi do · founded 2022
Developer of immunotherapies for cancer treatment. It offers Stealth-Body technology and Fc inert antibody platform for development of antibody therapies which include CPP-001 for Protein delivery, CPS-001 for Small molecule delivery, and CPR-001 for Gene delivery to cure cancer.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Moat
top 45%Patents
top 47%Funding
bottom 46%Talent
bottom 45%Innovation
bottom 40%Global
bottom 31%Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents
Patents: 5 patents matched (strict assignee match) · 5 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Mar 2026)
Funding rounds
- Mar 2026Seed$2.4M
Founders & team
Investors
Kudos Ventures, Y-Biologics, BMI Korea, SU Investment, Kite Entrepreneurship Foundation, Korea Omega Investment Corp
#8
Series B · Yuseong District, Hoseo · founded 2021 · 16 employees$18Mraised▾
Series B · Yuseong District, Hoseo · founded 2021 · 16 employees
Developer of drugs for the treatment of cancer. The company has developed a proprietary treatment-based Trio technology platform known as Oar1, Oar2, and Oar3 that detects targets, and induces cancer cell death. The technology is applied for various diseases, inflammation, autoimmunity, including cancer.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 38%Funding
top 39%Patents
top 41%Innovation
top 47%Talent
bottom 49%Market
bottom 34%Moat: Editorial + unicorn rating 4/10 · IP moat: 18 patents
Funding: Raised $18.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) · Last round Series B (Jul 2025)
Patents: 18 patents matched (strict assignee match) · 18 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Jul 2025Series B$18M
- Feb 2022Seed—
Founders & team
Investors
KB Investment, IMM Investment, WOORI Venture Partners, Shinhan Venture Investment, Hyundai Venture Investment, Regent Partners
#9
Series B · Yuseong, Daejeon · founded 2021 · 23 employees$10.1Mraised▾
Series B · Yuseong, Daejeon · founded 2021 · 23 employees
Developer of small molecule immuno-oncology drugs. The company's lead compounds include 'SCB001' and 'SCB002', which are small-molecular compounds that regulate the activity of immune cells in tumors. It develops a pipeline for NSCLC, Pancreatic cancer, and more.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 42%Moat
top 45%Patents
top 50%Talent
bottom 45%Innovation
bottom 38%Market
bottom 37%Funding: Raised $10.1M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) · Last round Series B (Sep 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Patents: 4 patents matched (strict assignee match) · 4 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Funding rounds
- Sep 2025Series B$10.1M
- 2023Series A—
- 2022Seed—
Founders & team
Investors
Union Investment Partners, Pioneerinvest, Kolon Investments, Enlight Ventures, iM Investment Partners, Korea Investment Holdings
#10
Series B · Daegu, Daegu · founded 2018 · 18 employees$3.7Mraised▾
Series B · Daegu, Daegu · founded 2018 · 18 employees
Developer of anticancer drugs and adjuvants. The company develops radiation-sensitive drugs and chemotherapy enhancers for radiation therapy. The flagship product is VS-101 a combination with radiation therapy head and neck cancers.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Moat
top 32%Patents
top 39%Funding
top 47%Innovation
top 50%Global
bottom 40%Market
bottom 36%Moat: Editorial + unicorn rating 5/10 · IP moat: 98 patents
Patents: 98 patents matched (strict assignee match) · 12 filings since 2022 vs 33 in 2017-21 · Latest publication 2026
Funding: Raised $3.7M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) · Last round Series B (Sep 2025)
Funding rounds
- Sep 2025Series B—
- Apr 2022Series A$3.7M
Investors
Enlight Ventures, POSCO Capital, Samho Green Investment, ST Capitals
#11
Series B · Seoul, Seoul · founded 2018 · 41 employees$17.6Mraised▾
Series B · Seoul, Seoul · founded 2018 · 41 employees
Developer of anti-cancer drugs based on Proteolysis Targeting Chimera. It has an inhibitor technology that breaks down the target protein and expects the desired therapeutic efficacy by binding the target protein related to the disease targeted for degradation near the E3 ligase that can initiate the proteolysis system.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 39%Talent
bottom 49%Market
bottom 39%Tech
bottom 37%Global
bottom 37%Funding: Raised $17.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series B (Dec 2024)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Market: 41 employees (top 41% of Life Sciences) · Top-50,000,000 web property
Funding rounds
- Dec 2024Series B$17.6M
Founders & team
Investors
Solidus Investment, Shinyoung Asset Management, Mint Venture Partners, Atinum Investment, QUAD, Korean Development Bank
#12
Seed · Cheongju-si, Chungcheongbuk-do · founded 2024$687Kraised▾
Seed · Cheongju-si, Chungcheongbuk-do · founded 2024
Developer of antibody-conjugated nanogel platform for targeted cancer therapeutics delivery. The platform technology aims to improve drug delivery, efficacy, and sustainability in cancer treatment. It focuses on developing treatments for difficult-to-treat cancers and solid tumors. The platform allows for direct injection into solid tumor sites. It can be customized into multi-antibody combination therapeutics and adheres to target tissues.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
bottom 49%Talent
bottom 45%Global
bottom 33%Funding: Raised $687k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Nov 2025)
Talent: 1 named leader on record
Global: Single-market focus (South Korea)
Audience (LinkedIn): 54 LinkedIn followers
Funding rounds
- Nov 2025Seed$687K
Founders & team
Investors
FuturePlay
Funding & investor landscape
$3.8Btotal disclosed funding
55companies funded
79disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Sj Lee
CEO · Orum Therapeutics
Woosung Son
CEO · NOVOREX
Kim Seop
CEO · Must Bio
Hongseok Jo
Co-Founder · MediMabBio
Jennifer Kang
Co-Founder & Co-CEO · MediMabBio
Tae-Erk Kim
Co-Founder & CEO · CrossPoint Therapeutics
Seongho Woo
CEO · TRIOAR
Chang Lee
CEO · SCBIO
Servo Optical
CEO · Uvic Steratics
Jongseong Kim
Founder & CEO · OncoLaB
Young-Whan Park
Founder & CEO · Avelos Therapeutics
J Han
Founder · Daan Biotherapeutics
Prism market signals · South Korea · country-scoped Prism corpus, 1,034,939 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · South Korea
How research on Oncology & Cancer Therapeutics is moving in South Korea
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,493 South Korea-affiliated papers.
research sentiment over time
201620222026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 66% → 73% across 2016–2026.
top research entities
- Ministry of Education247
- Seoul National University134
- National Cancer Center127
- Sungkyunkwan University117
- Yonsei University105
leading researchers
Hongyoon Choi · Sehhoon Park · Su Yeon Lim · Nayoung Kim · Areum Jo · Gamin Kim · Hye Min Kim · Seung Hyuck Jeon
▲
Breakthroughs559 · 37%
▼ 40%→38% share
▼0.9× share momentum1 median citations97% since 2021mostly methods-led
Tumor microenvironment research is surging — South Korean breakthrough papers rose from 8 to 257, with immunotherapy emerging at 218 papers.
rising sub-themes (early→recent)
- Tumor microenvironment8→257
- Immune system2→205
- Cancer research6→178
- Cancer cell1→37
- Immune checkpoint1→28
Newly emergingImmunotherapy 0→218 · Cancer immunotherapy 0→129 · Cytotoxic T cell 0→33
Landmark Pan-cancer single-cell landscape of tumor-infiltrating T cells · 1,311 cites
◆
Advancements704 · 47%
▲ 20%→47% share
▲2.4× share momentum2 median citations95% since 2021mostly empirical
Advancements field-share tripled to 47% — tumor microenvironment papers scaled from 5 to 371, dominating South Korean oncology progress.
rising sub-themes (early→recent)
- Tumor microenvironment5→371
- Immune system4→262
- Cancer research8→246
- Immunotherapy2→234
- Cancer immunotherapy3→104
Newly emergingColorectal cancer 0→43 · Immune checkpoint 0→38 · Breast cancer 0→36
Landmark Exosomes Derived from Mesenchymal Stem Cells Suppress Angiogenesis by Down-Regulating VEGF Expression in Breast Cancer C · 652 cites
▼
Concerns120 · 8%
▼ 10%→8% share
▼0.8× share momentum3 median citations92% since 2021mostly reviews
Immunotherapy safety concerns are newly emerging — 63 concern-flagged papers appeared alongside tumor microenvironment risks at 57 papers.
rising sub-themes (early→recent)
- Immune system1→49
- Cancer cell1→4
- Metastasis1→4
Newly emergingImmunotherapy 0→63 · Tumor microenvironment 0→57 · Cancer immunotherapy 0→32
Landmark Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects · 878 cites
RESEARCH HOTSPOTS · South Korea
Where oncology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Seoul604 · +0.59
Daejeon140 · +0.62
Seongnam-si72 · +0.52
Gwangju63 · +0.60
Daegu52 · +0.50
Ulsan49 · +0.54
Busan45 · +0.52
Incheon43 · +0.49
Suwon43 · +0.61
Jeonju15 · +0.51
PATENT SIGNAL · South Korea
Who's filing oncology patents in South Korea
South Korea oncology patent filing is accelerating — 367 filings from 129 assignees (2016–2025), led by Korea Advanced INST SCI & TECH, UNIV Yonsei IACF, UNIV Ulsan Found IND COOP; annual filings 4→73.
367 filings129 assigneespeak 73/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Korea Advanced INST SCI & TECH27
- UNIV Yonsei IACF23
- UNIV Ulsan Found IND COOP19
- ASAN Found18
- Seoul NAT UNIV R&DB Foundation18
- GI Innovation17
- Genemedicine16
- Samsung15
Common questions
How many Oncology companies are there in South Korea?
Radar tracks 232 indexable Oncology companies headquartered in South Korea that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in South Korea?
The Oncology companies in South Korea on this list have raised a combined $3.8B in disclosed equity funding across 55 funded companies.
Which is the highest-funded Oncology company in South Korea?
Cellid is the highest-funded Oncology company in South Korea, with $2.4B in disclosed equity funding.
How many Oncology companies in South Korea are funded?
55 of the 232 Oncology companies in South Korea on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in South Korea?
1 Oncology company in South Korea on this list is valued at $1B or more.
Who are the top investors in South Korea Oncology companies?
The most active investors in South Korea Oncology companies on this list include Korea Investment Holdings, IMM Investment, DSC Investment, UTC Investment, Wooshin Venture Investment.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.